Entries Invited for 1997 Rose Kushner Writing Awards

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 1
Volume 6
Issue 1

BETHESDA, Md--The American Medical Writers Association is accepting applications for the 1997 Rose Kushner Awards for Writing Achievement in the Field of Breast Cancer. A cash award of $1,000 for the winning entry in each of five categories will be provided through a grant from Zeneca Pharmaceuticals.

BETHESDA, Md--The American Medical Writers Association is acceptingapplications for the 1997 Rose Kushner Awards for Writing Achievement inthe Field of Breast Cancer. A cash award of $1,000 for the winning entryin each of five categories will be provided through a grant from ZenecaPharmaceuticals.

The awards were established in 1990 as a memorial tribute to Rose R.Kushner, a former member of the Association and a pioneer in breast cancereducation and patient advocacy. A survivor of breast cancer for 16 years,Rose Kushner died on January 7, 1990, at the age of 60.

Award categories include published lay articles (newspapers or magazines),published scientific articles (journals), brochures and monographs, books(medical and lay audiences), and scripts for video, film, or radio (medicaland lay audi-ences). Entries must have been published or shown from March1996 through March 1997.

The competition is open to AMWA and non-AMWA members. Entries may besubmitted by persons other than the writer, but the award, presented atthe AMWA Annual Conference, goes only to the writer.

The deadline for entries is May 10, 1997. For more information, contactthe American Medical Writers Association, 9650 Rockville Pike, Bethesda,MD 20814-3998. Telephone: 301-493-0003; Fax: 301-493-6384.

Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content